IVAC M uID

Drug Profile

IVAC M uID

Alternative Names: IVAC MUTANOME; Melanoma RNA vaccine personalised - BioNTech/Ribological/TRON; Personalised melanoma vaccine - BioNTech/TRON

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioNTech; Ribological; TRON
  • Class Cancer vaccines; RNA vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer; Malignant melanoma

Most Recent Events

  • 06 Sep 2017 BioNTech, TRON and EUFETS plan a phase I trial for Breast cancer (Second-line therapy or greater) in Germany, Belgium, Sweden and France
  • 05 Jul 2017 Efficacy data from a phase I trial in Malignant melanoma released by BioNTech
  • 01 Sep 2016 Phase-I clinical trials in Breast cancer in Germany (Intralymphatic) (NCT02316457)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top